12,008 Shares in Scholar Rock Holding Corporation $SRRK Purchased by SG Americas Securities LLC

SG Americas Securities LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 12,008 shares of the company’s stock, valued at approximately $447,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Strs Ohio bought a new position in shares of Scholar Rock during the first quarter valued at approximately $77,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Scholar Rock in the 2nd quarter worth approximately $94,000. Mirae Asset Global Investments Co. Ltd. increased its position in Scholar Rock by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,668 shares of the company’s stock valued at $130,000 after buying an additional 500 shares in the last quarter. Inceptionr LLC bought a new position in Scholar Rock during the 2nd quarter valued at approximately $205,000. Finally, MN Wealth Advisors LLC purchased a new position in Scholar Rock during the third quarter valued at $268,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

SRRK has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Friday, November 14th. Citigroup assumed coverage on shares of Scholar Rock in a research note on Friday, January 9th. They set a “buy” rating and a $55.00 price objective for the company. Barclays lifted their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. increased their price target on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $50.14.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $44.29 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of -14.06 and a beta of 0.63. The business has a 50-day simple moving average of $43.73 and a two-hundred day simple moving average of $37.32. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $48.28.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same quarter in the previous year, the firm earned ($0.66) EPS. On average, analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other Scholar Rock news, insider Mo Qatanani sold 14,898 shares of Scholar Rock stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $46.71, for a total value of $695,885.58. Following the completion of the sale, the insider owned 85,660 shares of the company’s stock, valued at approximately $4,001,178.60. The trade was a 14.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David Hallal sold 57,450 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the sale, the chief executive officer owned 1,541,645 shares of the company’s stock, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 305,687 shares of company stock valued at $13,540,573 in the last ninety days. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).